Fabrication of nanocrystal forms of ᴅ-cycloserine and their application for transdermal and enteric drug delivery systems

• Hsuan-Ang Tsai,
• Tsai-Miao Shih,
• Theodore Tsai,
• Jhe-Wei Hu,
• Yi-An Lai,
• Jui-Fu Hsiao and
• Guochuan Emil Tsai

Beilstein J. Nanotechnol. 2024, 15, 465–474, doi:10.3762/bjnano.15.42

• Biobehavioral Sciences, UCLA School of Medicine, 10833 Le Conte Ave, Los Angeles, CA 90095, USA 10.3762/bjnano.15.42 Abstract ᴅ-cycloserine (DCS), an FDA-approved medicine for the treatment of tuberculosis, is also a partial agonist at the glycine recognition site of N-methyl-ᴅ-aspartate (NMDA) receptor and

• the treatment of CNS disorders. Keywords: ᴅ-cycloserine; drug delivery system; enteric capsules; N-methyl-ᴅ-aspartate; nanocrystals; NMDA receptor agonist; transdermal reservoir; Introduction Tuberculosis (TB) is a prevalent respiratory disease caused by Mycobacterium tuberculosis. According to the

• Global 2020 Tuberculosis Report by the World Health Organization (WHO), a total of 1.4 million people died of TB [1]. ᴅ-cycloserine (DCS; ᴅ-4-amino-3-isoxazolidone), a cyclic analog of ᴅ-alanine, has been one of the remedies to treat TB since late 1950s, and is on the WHO list of essential medicines